EXAS Stock Recent News

EXAS LATEST HEADLINES

EXAS Stock News Image - zacks.com

The global demographic shift is reshaping healthcare demand, driving long-term investment in pharmaceuticals, medical devices, home care and digital health.

zacks.com 2025 Apr 14
EXAS Stock News Image - businesswire.com

MADISON, Wis.--(BUSINESS WIRE)--Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced the publication of a comprehensive review in JAMA Oncology that strengthens the evidence supporting the Oncotype DX Breast Recurrence Score test. The peer-reviewed article titled, “Genomic Assays for Breast Cancer in Diverse Populations: Prognostic and Predictive Insights,” affirms that the Oncotype DX test provides accurate and reliable information t.

businesswire.com 2025 Apr 14
EXAS Stock News Image - businesswire.com

MADISON, Wis.--(BUSINESS WIRE)--Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that the company plans to release its first quarter 2025 financial results after the close of the U.S. financial markets on May 1, 2025. Following the release, company management will host a webcast and conference call at 5 p.m. ET to discuss financial results and business progress. First quarter 2025 webcast & conference call details Date: Thursd.

businesswire.com 2025 Apr 01
EXAS Stock News Image - businesswire.com

MADISON, Wis.--(BUSINESS WIRE)--Exact Sciences Launches the Cologuard Plus™ Test, Transforming Colorectal Cancer Screening.

businesswire.com 2025 Mar 31
EXAS Stock News Image - zacks.com

EXAS' solid focus on advancing new solutions bodes well for investors. However, a dull macroeconomic condition adds to the worry.

zacks.com 2025 Mar 27
EXAS Stock News Image - seekingalpha.com

Natera: Growth Looks Unstoppable, Positive EPS Just A Matter Of Time

seekingalpha.com 2025 Mar 17
EXAS Stock News Image - businesswire.com

BAAR, Switzerland--(BUSINESS WIRE)--Exact Sciences, a leading provider of cancer screening and diagnostic tests, today announced the presentation of new data further reinforcing the utility of its Oncotype DX Breast Recurrence Score® test at the 19th St. Gallen International Breast Cancer Conference in Vienna, Austria. A UK study1 explored the benefits of shifting the testing point to the pre-surgery setting by utilizing Oncotype DX on breast cancer core biopsy samples instead of surgical speci.

businesswire.com 2025 Mar 12
EXAS Stock News Image - zacks.com

If the cancer space appeals to you, it's time to consider stocks like Novartis, Exact Sciences and Monte Rosa.

zacks.com 2025 Mar 07
EXAS Stock News Image - fool.com

Warren Buffett, arguably the greatest investor of all time, once said it is wise for investors to be fearful when others are greedy. One way to apply this advice from the Oracle of Omaha is to look at a soaring stock market and identify companies that aren't performing nearly as well -- or are just performing poorly -- but still have attractive prospects.

fool.com 2025 Feb 24
EXAS Stock News Image - businesswire.com

MADISON, Wis.--(BUSINESS WIRE)--Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that company management will participate in the following conferences and invited investors to participate by webcast. TD Cowen Health Care Conference, Boston Fireside chat on Monday, March 3, 2025 at 10:30 a.m. ET Raymond James Institutional Investors Conference, Orlando Presentation on Tuesday, March 4, 2025 at 1:05 p.m. ET The webcasts can be acces.

businesswire.com 2025 Feb 24
10 of 50